Moderna stock price forecast remains volatile, currently trading near $98, with analysts projecting a potential short-term range between $92 and $105 based on biotech sector sentiment and ongoing mRNA pipeline updates. Institutional flows show mixed positions, suggesting cautious optimism. After this shocking news, is the stock a buy, with the idea that efforts will spur growth -- or is it a sell? Let's find out. The market expects Moderna (MRNA) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The Moderna stock price forecast for Q3 remains bullish, with JPMorgan revising target to $